Sanara MedTech (NASDAQ:SMTI) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Sanara MedTech (NASDAQ:SMTI) issued its quarterly earnings data on Tuesday. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03), FiscalAI reports. The firm had revenue of $28.14 million during the quarter, compared to analyst estimates of $28.95 million. Sanara MedTech had a negative net margin of 31.23% and a negative return on equity of 3.19%.

Sanara MedTech Price Performance

NASDAQ SMTI traded up $0.13 during midday trading on Tuesday, hitting $34.38. The company had a trading volume of 367,130 shares, compared to its average volume of 98,561. The company has a market capitalization of $314.92 million, a PE ratio of -9.12 and a beta of 1.12. The company has a current ratio of 2.28, a quick ratio of 2.05 and a debt-to-equity ratio of 6.59. The firm has a 50-day moving average price of $25.39 and a 200-day moving average price of $21.81. Sanara MedTech has a twelve month low of $16.05 and a twelve month high of $35.95.

Analyst Upgrades and Downgrades

SMTI has been the subject of a number of research reports. Freedom Capital downgraded Sanara MedTech from a “strong-buy” rating to a “hold” rating in a report on Monday, August 3rd. Zacks Research upgraded shares of Sanara MedTech from a “strong sell” rating to a “hold” rating in a research note on Wednesday, June 10th. Lake Street Capital lowered shares of Sanara MedTech from a “buy” rating to a “hold” rating and set a $35.00 price target on the stock. in a research report on Thursday, July 30th. HC Wainwright cut shares of Sanara MedTech from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $36.00 to $35.00 in a research note on Thursday, July 30th. Finally, Wall Street Zen downgraded shares of Sanara MedTech from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 1st. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $35.00.

Institutional Trading of Sanara MedTech

Several large investors have recently modified their holdings of SMTI. Vanguard Group Inc. raised its stake in Sanara MedTech by 3.4% in the third quarter. Vanguard Group Inc. now owns 182,032 shares of the company’s stock valued at $5,776,000 after purchasing an additional 6,049 shares in the last quarter. Royal Bank of Canada grew its stake in Sanara MedTech by 127.3% during the fourth quarter. Royal Bank of Canada now owns 117,643 shares of the company’s stock worth $2,747,000 after buying an additional 65,887 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Sanara MedTech by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 79,049 shares of the company’s stock valued at $1,846,000 after buying an additional 546 shares in the last quarter. Marshall Wace LLP raised its position in shares of Sanara MedTech by 144.3% in the 2nd quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock valued at $2,030,000 after buying an additional 42,237 shares in the last quarter. Finally, State Street Corp raised its position in shares of Sanara MedTech by 1.1% in the 4th quarter. State Street Corp now owns 62,289 shares of the company’s stock valued at $1,454,000 after buying an additional 690 shares in the last quarter. 8.10% of the stock is owned by institutional investors and hedge funds.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.